RETATRUTIDE
information
What is Retatrutide?
Retatrutide, a synthetic peptide created by Eli Lilly, is also known by its development code LY3437943. This peptide acts as a triple receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG) receptors
Both GLP-1 and GIP are incretin hormones that stimulate insulin secretion and modulate immune responses. Moreover, the activation of GCG receptors by Retatrutide is thought to boost metabolic rate and increase energy expenditure
Retatrutide Dosing | Research Only
Researchers are advised to follow specific dosing protocols to ensure the safety and efficacy of retatrutide in weight loss studies. The dosing regimen starts with a low dose of 1 mg per week, which is gradually increased to minimize side effects. The recommended schedule is as follows:
Weeks 1-4: Start with 1 mg weekly
Weeks 5-8: Increase to 2 mg weekly
Weeks 9-12: Increase to 4 mg weekly
Weeks 13-16: Increase to 8 mg weekly
Week 17+: Reach the full dose of 12 mg weekly
It’s essential that researchers do not exceed the maximum recommended dosage of 12 mg per week. Retatrutide is designed for once-weekly subcutaneous administration, and due to its extended half-life, it can be injected at any time of day, with or without food.